羧基麦芽糖铁后持续性和严重低磷血症的危险因素及影响
基于PHOSPHARE-IDA随机临床试验245例缺铁性贫血患者,羧基麦芽糖铁(FCM)是发生低磷血症的唯一一致危险因素(OR 38.37,95%CI 16.62-88.56,P<0.001)。仅FCM组出现严重低磷血症(11.3%,13/115)和持续性低磷血症(40.0%,46/115),且低磷血症越严重,骨矿物质代谢紊乱越明显。
要点
- FCM是发生低磷血症的唯一一致危险因素(OR 38.37,95%CI 16.62-88.56,P<0.001)。
- 仅FCM组出现严重低磷血症(11.3%,13/115)和持续性低磷血症(40.0%,46/115)。
- 低磷血症越严重,iFGF23、PTH、碱性磷酸酶升高及1,25(OH)2D、离子钙降低越显著(均P<0.05)。
核心结论
- FCM治疗是低磷血症的唯一一致危险因素。
- FCM后发生严重或持续性低磷血症的患者表现出更严重的骨矿物质代谢紊乱。
- 骨标志物变化在低磷血症缓解后仍持续,提示对骨骼的持续影响可能有助于解释FCM与骨软化症和骨折的关联。
研究设计与样本
- 分析PHOSPHARE-IDA随机临床试验数据,纳入美国30家门诊诊所245例18岁及以上缺铁性贫血患者,接受静脉羧基麦芽糖铁(FCM)或异麦芽糖酐铁(FDI)治疗。
主要发现
- FCM是发生低磷血症(<2.0 mg/dL)的唯一一致危险因素(对比FDI的OR 38.37,95%CI 16.62-88.56,P<0.001)。
- 仅FCM组出现严重低磷血症(<1.0 mg/dL;11.3%;13/115)或持续性低磷血症(研究结束时<2.0 mg/dL;40.0%;46/115)。
- 低磷血症越严重,iFGF23、PTH和碱性磷酸酶升高越显著,1,25(OH)2D和离子钙降低越显著(均P<0.05)。
- 持续性低磷血症与缓解组相比,iFGF23、PTH、1,25(OH)2D和N端前胶原-1肽水平变化显著更大(均P<0.01),但两组碱性磷酸酶升高相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations. OBJECTIVE: This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous iron treatment. METHODS: We analyzed data from the PHOSPHARE-IDA randomized clinical trials, comprising 245 patients aged 18 years or older with iron deficiency anemia at 30 outpatient clinics in the United States who received intravenous ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Outcome measures included serum phosphate, intact fibroblast growth factor-23 (iFGF23), 1,25-dihydroxyvitamin D (1,25(OH)2D), ionized calcium, parathyroid hormone (PTH), and alkaline phosphatase. RESULTS: FCM was the only consistent risk factor for incident hypophosphatemia (< 2.0 mg/dL; odds ratio vs FDI: 38.37; 95% CI: 16.62, 88.56; P < 0.001). Only FCM-treated patients developed severe hypophosphatemia (< 1.0 mg/dL; 11.3%; 13/115) or persistent hypophosphatemia (< 2.0 mg/dL at study end; 40.0%; 46/115). More severe hypophosphatemia associated with significantly greater increases in iFGF23, PTH, and alkaline phosphatase, and more severe decreases in 1,25(OH)2D and ionized calcium (all P < 0.05). Patients with persistent vs resolved hypophosphatemia demonstrated significantly greater changes in iFGF23, PTH, 1,25(OH)2D, and N-terminal procollagen-1 peptide levels (all P < 0.01), but alkaline phosphatase increased similarly in both groups. CONCLUSION: Treatment with FCM was the only consistent risk factor for hypophosphatemia. Patients who developed severe or persistent hypophosphatemia after FCM treatment manifested more severe derangements in bone and mineral metabolism. Changes in bone biomarkers continued beyond resolution of hypophosphatemia, suggesting ongoing effects on bone that may help explain the association of FCM with osteomalacia and fractures.
引用
- Schaefer B, Zoller H, Wolf M, et al. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. J Clin Endocrinol Metab. 2022. PMID: 34850000. doi:10.1210/clinem/dgab852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。